Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CYTH Nasdaq 2833 https://www.cyclotherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclo Therapeutics Inc

Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock - Apr 10th, 2024 12:13 pm
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - Mar 18th, 2024 1:05 pm
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease - Mar 14th, 2024 1:34 pm
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results - Mar 13th, 2024 9:04 pm
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office - Jan 29th, 2024 2:15 pm
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. - Dec 27th, 2023 9:15 pm
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 - Dec 18th, 2023 2:15 pm
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results - Dec 14th, 2023 9:01 pm
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024 - Nov 21st, 2023 1:05 pm
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results - Nov 15th, 2023 1:05 pm
Several Insiders Invested In Cyclo Therapeutics Flagging Positive News - Nov 2nd, 2023 11:12 am
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results - Oct 30th, 2023 8:01 pm
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million - Oct 23rd, 2023 12:05 pm
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference - Oct 5th, 2023 12:05 pm
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference - Sep 21st, 2023 1:35 pm
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement - Sep 21st, 2023 12:05 pm
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results - Aug 15th, 2023 12:05 pm
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. - Aug 2nd, 2023 12:16 pm
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 - Jun 29th, 2023 5:32 pm
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update - Jun 13th, 2023 8:01 pm